{
  "id": 2453669,
  "title": "Si-Bone chief op & financial officer sells $337,138 in stock",
  "url": "https://urgent.news/2026/08/21/si-bone-chief-op-financial-officer-sells-337-138-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-21T23:31:16.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/sibone-chief-op--financial-officer-sells-337138-in-stock-93CH-4872226"
  },
  "original_language": "en",
  "account": "Anshul Maheshwari, Chief Operating and Financial Officer at SI-BONE, Inc., divested 16,975 shares of the company's stock, generating a total of $337,138. The transactions were carried out on August 19 and August 21, 2026. On August 19, he sold 5,747 shares at prices between $19.50 and $19.67 per share. Two days later, on August 21, an additional 11,228 shares were sold, with prices ranging from $20.00 to $20.05 per share. These stock sales were executed under a pre-planned 10b5-1 trading strategy, initiated on December 17, 2025. The timing aligns with the stock's impressive 29% increase over the past six months. However, InvestingPro analysis indicates the stock is currently overvalued, positioning it among the Most Overvalued companies. Post these transactions, Mr. Maheshwari retains 234,920 shares of SI-BONE common stock. This amount also includes 167,604 shares that will become available upon the settlement of restricted stock units. For a deeper analysis of SI-BONE's financial status and valuation, investors can refer to the Pro Research Report, available for this and over 1,400 other US equities. Notably, SI-BONE reported its Q2 2026 earnings, exceeding market expectations with an adjusted loss of $0.09 per share, surpassing analysts' forecasted $0.16 loss. Revenue for the quarter rose by 15.2% to $56 million, slightly surpassing the expected $55.92 million. Despite this positive performance, after-hours trading saw a slight dip in the stock's value as investors evaluated the company's future prospects and spending strategies. Canaccord Genuity maintained its Buy rating for SI-BONE, with a price target of $27.00, citing robust US surgeon engagement and procedural volume growth. Additionally, the company increased its revenue and operating expense guidance based on these earnings.",
  "summary": null,
  "key_points": [
    "Anshul Maheshwari sold 16,975 shares of SI-BONE stock, earning $337,138",
    "Transactions occurred on August 19 and August 21, 2026",
    "Shares were sold under a pre-planned 10b5-1 trading strategy"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}